# Clinical Cases: Skin Structure and Function ## Case 1: Epidermolysis Bullosa - Dermal-Epidermal Junction Disorder ### Patient Presentation **Demographics:** 2-day-old male neonate **Chief Complaint:** Blistering and skin erosions noted at birth **History of Present Illness:** The infant was born at term via vaginal delivery. At birth, the nursing staff noted several blisters and areas of skin loss on his hands, feet, and around his mouth. Minimal handling causes new blisters to form. The parents have no family history of similar skin conditions. **Physical Examination:** - General: Full-term neonate, appropriate size - Skin: - Multiple tense blisters on hands and feet - Erosions at sites of previous blisters - Perioral erosions (from sucking) - New blister formation with gentle friction - No infectious signs ### Workup and Results **Skin Biopsy:** - Light microscopy: Subepidermal blister formation - Immunofluorescence mapping: Separation at lamina lucida - EM: Absent hemidesmosomes and anchoring filaments **Genetic Testing:** - Mutation in LAMA3 gene (laminin-332) - Consistent with junctional epidermolysis bullosa ### Clinical Image ![Epidermolysis Bullosa](case_01_image.jpg) *Clinical photograph demonstrating tense blisters and erosions on the hand of an infant with epidermolysis bullosa, showing characteristic fragility at sites of friction.* ### Diagnosis **Junctional Epidermolysis Bullosa** Classification: - Blister formation at the dermal-epidermal junction (lamina lucida) - Due to mutations in components of the anchoring complex ### Discussion This case illustrates dermal-epidermal junction disorders: - **DEJ Components**: The lecture describes the complex architecture of the dermal-epidermal junction, including hemidesmosomes, anchoring filaments (containing laminin-332), and anchoring fibrils (type VII collagen). - **Blistering from Junction Disruption**: The lecture explains that disruption of the dermal-epidermal junction leads to blistering diseases. The level of separation (within epidermis, at DEJ, or in dermis) determines the type of blistering disorder. - **Type VII Collagen**: The lecture notes that type VII collagen forms anchoring fibrils that connect the basement membrane to the dermis. Mutations or antibodies against type VII collagen cause dystrophic epidermolysis bullosa or epidermolysis bullosa acquisita, respectively. - **Mechanical Fragility**: The DEJ is designed to withstand shearing forces. Defects in any component lead to mechanical fragility and blister formation with minimal trauma. ### Treatment Plan 1. **Wound Care:** - Non-adherent dressings - Gentle handling - "minimal touch" technique - Protective padding at friction sites 2. **Nutrition:** - Monitor feeding (oral blisters can impair intake) - May need soft nipples or alternative feeding methods 3. **Infection Prevention:** - Daily wound assessment - Topical antibiotics if concerning for infection - Low threshold for cultures 4. **Multidisciplinary Care:** - Dermatology, pediatrics, genetics, nutrition - Physical/occupational therapy as child grows - Genetic counseling for family 5. **Long-term Monitoring:** - Growth and development - Screening for esophageal strictures - SCC surveillance in dystrophic forms ### Teaching Points 1. The DEJ consists of hemidesmosomes, lamina lucida, lamina densa, and anchoring fibrils 2. Type VII collagen forms anchoring fibrils connecting basement membrane to dermis 3. DEJ disruption causes blistering diseases (mechanical fragility) 4. Immunofluorescence mapping localizes the level of blister formation 5. Different EB subtypes result from mutations in specific junction components --- ## Case 2: Vitiligo - Melanocyte Destruction ### Patient Presentation **Demographics:** 28-year-old female **Chief Complaint:** Expanding white patches on hands and face **History of Present Illness:** The patient noticed depigmented patches on the dorsum of her hands 6 months ago. The patches have slowly expanded and new patches appeared on her face around her eyes and mouth. She has no symptoms (no itching, pain, or scaling). She has a history of hypothyroidism. **Family History:** - Mother has vitiligo - Aunt has type 1 diabetes **Physical Examination:** - Skin: - Sharply demarcated, depigmented (chalk-white) macules and patches - Distribution: Dorsal hands, periorbital, perioral - Bilateral and symmetric - No scale, no atrophy - Wood lamp: Enhanced depigmentation (bright white fluorescence) - Thyroid: Non-tender, no nodules ### Workup and Results **Laboratory Studies:** - TSH: 8.2 mU/L (elevated - known hypothyroidism) - Anti-TPO antibodies: Positive **Wood Lamp Examination:** - Bright white fluorescence in affected areas - Helps delineate extent of involvement ### Clinical Image ![Vitiligo](case_01_image.jpg) *Clinical photograph showing characteristic depigmented patches of vitiligo with sharply demarcated borders, demonstrating the typical distribution around the periorbital and perioral areas.* ### Diagnosis **Vitiligo (Generalized/Common Type)** Features: - Acquired depigmentation - Autoimmune destruction of melanocytes - Associated autoimmune conditions (thyroid disease) - Family history of autoimmunity ### Discussion This case illustrates melanocyte biology and destruction: - **Melanocyte Origin**: The lecture describes how melanocytes originate from neural crest cells and reside in the stratum basale of the epidermis. - **Autoimmune Destruction**: The lecture identifies vitiligo as resulting from autoimmune destruction of melanocytes. T-cell mediated destruction leads to complete loss of melanin production in affected areas. - **Melanin Function**: The lecture explains that melanin produced by melanocytes (eumelanin = brown/black; pheomelanin = red/yellow) protects against UV radiation damage. Loss of melanocytes in vitiligo increases photosensitivity. - **Tyrosinase**: The lecture notes that tyrosinase is the rate-limiting enzyme in melanin synthesis. Antibodies against melanocyte antigens (including tyrosinase) may contribute to vitiligo pathogenesis. ### Treatment Plan 1. **Sun Protection:** - Sunscreen SPF 30+ (affected areas prone to sunburn) - Protective clothing 2. **Topical Therapy:** - Topical corticosteroids (first-line for limited disease) - Topical calcineurin inhibitors (tacrolimus) - face-safe - Trial for 3-6 months 3. **Phototherapy:** - Narrowband UVB for extensive disease - Stimulates melanocyte migration from hair follicles 4. **Cosmetic Options:** - Cosmetic camouflage (cover-up makeup) - Self-tanners (temporary) 5. **Screening:** - Annual thyroid function tests - Screen for other autoimmune conditions if symptoms develop ### Teaching Points 1. Melanocytes originate from neural crest and reside in stratum basale 2. Vitiligo results from autoimmune destruction of melanocytes 3. Tyrosinase is the rate-limiting enzyme in melanin synthesis 4. Vitiligo is associated with other autoimmune conditions (thyroid, diabetes) 5. Wood lamp examination enhances depigmented areas --- ## Case 3: Wound Healing Phases ### Patient Presentation **Demographics:** 45-year-old male with diabetes **Chief Complaint:** Non-healing foot ulcer for 3 months **History of Present Illness:** The patient has a chronic diabetic foot ulcer on the plantar surface of his right great toe. The wound has been present for 3 months despite wound care. He has peripheral neuropathy and does not feel pain in the affected area. He continues to walk on the foot without offloading. **Past Medical History:** - Type 2 diabetes mellitus (HbA1c 9.2%) - Peripheral neuropathy - Peripheral arterial disease **Physical Examination:** - Right foot: - 2 cm x 1.5 cm ulcer on plantar great toe - Wound bed: Pale, granular tissue with some slough - Minimal drainage - No surrounding erythema or warmth - Peripheral pulses: Diminished dorsalis pedis - Sensory: Absent protective sensation (10g monofilament negative) ### Workup and Results **Ankle-Brachial Index:** - Right ABI: 0.65 (moderate PAD) **Wound Culture:** - Mixed flora, no signs of deep infection **X-ray Foot:** - No osteomyelitis on plain films ### Clinical Image ![Chronic Wound](case_01_image.jpg) *Photograph of chronic diabetic foot ulcer demonstrating impaired wound healing with poor granulation tissue, reflecting the failure of normal wound healing progression from proliferative to remodeling phase.* ### Diagnosis **Chronic Non-Healing Diabetic Foot Ulcer** Contributing factors: - Impaired wound healing (hyperglycemia) - Peripheral arterial disease (poor perfusion) - Continued pressure/trauma (neuropathy) - Failure to progress through normal wound healing phases ### Discussion This case illustrates wound healing phases and impairment: - **Hemostasis and Inflammation**: The lecture describes the initial phases involving platelet plug formation, fibrin clot, and inflammatory cell recruitment. Chronic wounds often get "stuck" in the inflammatory phase. - **Proliferation Phase**: The lecture explains that granulation tissue formation, angiogenesis (driven by VEGF), and re-epithelialization occur during proliferation. This patient shows poor granulation, indicating impaired proliferation. - **Remodeling Phase**: The lecture describes how type III collagen is gradually replaced by type I collagen during remodeling, increasing wound strength to approximately 80% of normal. - **Factors Impairing Healing**: Diabetes impairs multiple wound healing phases through hyperglycemia-induced cellular dysfunction, impaired angiogenesis, and increased infection risk. PAD reduces oxygen and nutrient delivery. ### Treatment Plan 1. **Optimize Systemic Factors:** - Improve glycemic control (target HbA1c <7%) - Vascular assessment/intervention if indicated - Nutritional optimization 2. **Offloading:** - Total contact cast or removable walking boot - Essential to remove pressure from wound 3. **Wound Bed Preparation:** - Debridement of non-viable tissue - Moisture balance with appropriate dressings - Consider advanced wound therapies 4. **Infection Control:** - Monitor for signs of infection - Antibiotics if clinical infection develops 5. **Advanced Therapies (if no progress):** - Growth factors (becaplermin/PDGF) - Negative pressure wound therapy - Cellular/tissue-based products ### Teaching Points 1. Wound healing occurs in four phases: hemostasis, inflammation, proliferation, remodeling 2. VEGF drives angiogenesis during proliferation phase 3. Type III collagen is replaced by type I collagen during remodeling 4. Maximum wound strength is ~80% of normal skin 5. Chronic wounds often stall in the inflammatory phase --- ## Image Reference For visual reference of skin structure concepts, see: - Radiopaedia: [Skin anatomy](https://radiopaedia.org/articles/skin) - Structure - Wikipedia: [Epidermis](https://en.wikipedia.org/wiki/Epidermis) - Layers - Radiopaedia: [Wound healing](https://radiopaedia.org/articles/wound-healing) - Phases --- ## Learning Points 1. **Skin Layers**: Epidermis (from ectoderm), dermis (from mesoderm), hypodermis 2. **Keratinocyte Turnover**: ~28 days from stratum basale to stratum corneum 3. **Melanocyte Origin**: Neural crest; reside in stratum basale 4. **DEJ Function**: Connects epidermis to dermis; type VII collagen forms anchoring fibrils 5. **Wound Healing Phases**: Hemostasis, inflammation, proliferation (VEGF/angiogenesis), remodeling (type III to type I collagen)